Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Because the impairment of platelet function may cause excess peri-operative bleeding, pre-operative aspirin discontinuation and heparin bridging are common at cardiac surgery. We aimed to evaluate the impact of a low-molecular-weight-heparin (LMWH), enoxaparin, and unfractionated heparin (UFH) on coagulation parameters and peri-operative bleeding in patients undergoing elective coronary artery bypass grafting (CABG) surgery after aspirin discontinuation.

The specific hypothesis of this study was that a 12 h interval is sufficient not to cause excess peri-operative bleeding, and is therefore an optimal compromise between antithrombotic efficacy and haemorrhagic safety.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chieti
• Treatments: Calcium heparin; Dalteparin; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight

Criteria

Inclusion Criteria:

• Patients aged 35-75 years with 3-vessel coronary artery disease (CAD)

• Candidates to elective CABG

Exclusion Criteria:

• Other additional (valve, carotid, etc.) simultaneous surgery required,

• Off-pump surgery,

• Any altered liver and kidney laboratory parameters,

• A history of any haemorrhagic disorders,

• Platelet count <100,000 and >450.000/μL,

• Treatment with ticlopidine or clopidogrel in the last month.